These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 34421886)

  • 1. Predictive Value of the
    Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
    Front Immunol; 2021; 12():643282. PubMed ID: 34421886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.
    Chen M; Li P; Yao H; Liu F; Fu L; Wang Y; Zhu J; Xu Q; Liang H; Zhou Y; Wang Z; Deng Q; Chen W; Cao J; Chen X; Luo J
    Transl Androl Urol; 2023 Mar; 12(3):406-424. PubMed ID: 37032757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
    Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
    Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
    Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
    Wang Y; Chen L; Ju L; Xiao Y; Wang X
    Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
    Front Immunol; 2020; 11():590618. PubMed ID: 33391264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
    Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
    J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
    Zhang Y; Lin A; Li Y; Ding W; Meng H; Luo P; Zhang J
    Front Cell Dev Biol; 2020; 8():608969. PubMed ID: 33363171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
    Naranbhai V; Viard M; Dean M; Groha S; Braun DA; Labaki C; Shukla SA; Yuki Y; Shah P; Chin K; Wind-Rotolo M; Mu XJ; Robbins PB; Gusev A; Choueiri TK; Gulley JL; Carrington M
    Lancet Oncol; 2022 Jan; 23(1):172-184. PubMed ID: 34895481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
    Seitz RS; Hurwitz ME; Nielsen TJ; Bailey DB; Varga MG; Ring BZ; Metts CF; Schweitzer BL; McGregor K; Ross DT
    J Transl Med; 2022 Aug; 20(1):370. PubMed ID: 35974414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
    Front Immunol; 2020; 11():1900. PubMed ID: 32983112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
    Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
    JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.